comparemela.com

Paediatric Committee News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 .

Elizabeth colemanJohn mendittoCorporate communicationsLisata therapeutics incEuropean medicines agencyEuropean unionExchange commissionPaediatric committeePaediatric investigation planExecutive vice presidentChief medical officerPaediatric regulationFast trackOrphan drug designationRare pediatric disease designationPrivate securities litigation reform act

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines

Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed

Elizabeth colemanJohn mendittoEuropean medicines agencyPaediatric committeeLisata therapeutics incEuropean unionExchange commissionCorporate communicationsPaediatric investigation planExecutive vice presidentChief medical officerPaediatric regulationFast trackOrphan drug designationRare pediatric disease designationCendr platform

Lisata Therapeutics receives waiver for pediatric studies of certepetide in pancreatic cancer

Lisata Therapeutics Inc (NASDAQ:LSTA) has received a Paediatric Investigation Plan (PIP) waiver from the European Medicines Agency (EMA) for its lead.

Lisata therapeutics incEuropean medicines agencyPaediatric committeePaediatric investigation plan

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

CEL-SCI Corporation today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments. Clinical and Corporate Developments.

United statesGeert kerstenSecurities exchangeEuropean unionDrug administrationExchange commissionEuropean medicines agency paediatric committeeCorporate developmentsRegistration studyEuropean medicines agencyPaediatric committeeLeukocyte interleukinOrphan drugSecurities actSecurities exchange act

Cessatech: Cessatech announces positive topline data from study 0205 with its lead candidate CT001 for the treatment of pain in children supporting further advancement of CT001 -December 22, 2023 at 07:35 am EST

Press release from Companies Publicerat: 2023-12-22 13:33:27 Cessatech A/S: Cessatech announces positive topline data from study 0205 with its lead candidate.

Cessatechas cessatechJes trygvedPaediatric committeeInvestigation planPaediatric investigation planPrincipal investigator

vimarsana © 2020. All Rights Reserved.